Used in the synthesis of esomeprazole, a proton pump inhibitor for treating gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders. It acts as a key chiral intermediate in pharmaceutical manufacturing, enabling high enantioselectivity and improved metabolic stability in the final drug product. Its structure supports targeted inhibition of gastric acid secretion with greater efficacy compared to racemic counterparts.